症状性冠心病患者药物负荷SPECT与PET心肌灌注显像临床有效性的随机比较
该单中心随机试验将322例已知冠心病且疑有心肌缺血的患者分为药物负荷PET与衰减校正SPECT心肌灌注显像两组,各161例,随访12个月。主要终点诊断失败(60天内不必要造影或额外无创检查)仅7例(2.2%),PET组3例(1.9%)与SPECT组4例(2.5%)无显著差异(p=0.70);两组后续造影、血运重建及健康状况亦无显著差异(所有p≥0.20)。事后分析显示,PET高危显像者随访造影和血运重建率高于SPECT高危者,而PET低危者低于SPECT低危者(12个月导管检查交互p=0.001,12个月血运重建交互p=0.09)。
要点
- 药物负荷PET与SPECT心肌灌注显像在60天诊断失败率上无显著差异(PET组1.9% vs SPECT组2.5%,p=0.70)。
- 事后分析中,PET高危显像者12个月造影和血运重建率高于SPECT高危者,PET低危者则低于SPECT低危者。
- 两组在后续冠状动脉造影、血运重建及3、6、12个月健康状况上均无显著差异(所有p≥0.20)。
核心结论
- 在药物负荷心肌灌注显像中,PET与SPECT在60天诊断失败率、后续冠状动脉造影、血运重建及1年健康状况上均无显著差异。
- 事后分析提示PET心肌灌注显像的后续有创检查率比SPECT更符合高危特征。
研究设计与样本
- 单中心随机试验,2009年6月至2013年9月纳入已知冠心病且疑有心肌缺血的患者,随机接受PET或衰减校正SPECT药物负荷心肌灌注显像。
- 共322例可评估心肌灌注显像的患者被随机分组,PET组161例,SPECT组161例。
- 基线时88.8%患者服用阿司匹林,76.7%服用β受体阻滞剂,77.3%服用他汀。
- 检查后处理由转诊医师决定,随访12个月。
诊断标准与关键数值
- 主要终点诊断失败定义为心肌灌注显像后60天内不必要造影(≥1支血管狭窄<50%)或额外无创检查。
- 60天内诊断失败共7例(2.2%),PET组3例(1.9%)vs SPECT组4例(2.5%),p=0.70。
- 后续冠状动脉造影、血运重建及3、6、12个月健康状况两组比较所有p值≥0.20。
- 事后分析:随机模态与高危心肌灌注显像交互作用,12个月导管检查p=0.001,12个月血运重建p=0.09。
临床应用与阅片要点
- 在已知冠心病且症状提示缺血、已接受优化药物治疗的患者中,药物负荷PET与SPECT心肌灌注显像在60天诊断失败率上无显著差异。
- 事后分析中,PET高危显像者的后续造影和血运重建率高于SPECT高危者,PET低危者则低于SPECT低危者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: This study compared the clinical effectiveness of pharmacologic stress myocardial perfusion imaging (MPI) plus positron emission tomography (PET) with single-photon emission computed tomography (SPECT) in patients with known coronary artery disease (CAD) presenting with symptoms suggestive of ischemia.
BACKGROUND: Although PET MPI has been shown to have higher diagnostic accuracy in detecting hemodynamically significant CAD than SPECT MPI, whether this impacts downstream management has not been formally evaluated in randomized trials.
METHODS: This study consisted of a single-center trial in which patients with known CAD and suspected ischemia were randomized to undergo PET or attenuation-corrected SPECT MPI between June 2009 and September 2013. Post-test management was at the discretion of the referring physician, and patients were followed for 12 months. The primary endpoint was diagnostic failure, defined as unnecessary angiography (absence of ≥50% stenosis in ≥1 vessel) or additional noninvasive testing within 60 days of the MPI. Secondary endpoints were post-test escalation of antianginal therapy, referral for angiography, coronary revascularization, and health status at 3, 6, and 12 months.
RESULTS: A total of 322 patients with an evaluable MPI were randomized (n = 161 in each group). At baseline, 88.8% of patients were receiving aspirin therapy, 76.7% were taking beta-blockers, and 77.3% were taking statin therapy. Diagnostic failure within 60 days occurred in only 7 patients (2.2%) (3 [1.9%] in the PET group and 4 [2.5%] in the SPECT group; p = 0.70). There were no significant differences between the 2 groups in subsequent rates of coronary angiography, coronary revascularization, or health status at 3, 6, and 12 months of follow-up (all p values ≥0.20); however, when subjects were stratified by findings on MPI in a post hoc analysis, those with high-risk MPI on PET testing had higher rates of angiography and revascularization on follow-up than those who had SPECT MPI, whereas those undergoing low-risk PET studies had lower rates of both procedures than those undergoing SPECT (interaction between randomized modality ∗high-risk MPI for 12-month catheterization [p = 0.001] and 12-month revascularization [p = 0.09]).
CONCLUSIONS: In this contemporary cohort of symptomatic CAD patients who were optimally medically managed, there were no discernible differences in rates of diagnostic failure at 60 days, subsequent coronary angiography, revascularization, or patient health status at 1 year between patients evaluated by pharmacologic PET compared with those evaluated by SPECT MPI. Downstream invasive testing rates with PET MPI were more consistent with high-risk features than those with SPECT MPI. (Effectiveness Study of Single Photon Emission Computed Tomography [SPECT] Versus Positron Emission Tomography [PET] Myocardial Perfusion Imaging; NCT00976053).
引用
- Patel KK, Al Badarin F, Chan PS, et al. Randomized Comparison of Clinical Effectiveness of Pharmacologic SPECT and PET MPI in Symptomatic CAD Patients. JACC Cardiovasc Imaging. 2019. PMID: 31326480. doi:10.1016/j.jcmg.2019.04.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。